Compare iShares MSCI Singapore ETF (EWS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Singapore ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Singapore ETF trades at $31.6 (market cap $1.49B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 9.6× iShares MSCI Singapore ETF's market cap, and iShares MSCI Singapore ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Singapore ETF for 45 Days and Neurocrine Biosciences Inc for 23 Days on average.
| EWS | NBIX | |
|---|---|---|
Market Cap | $1.49B | $14.36B |
Volume | 2,142,305 | 1,237,180 |
Sector | Broad Market / Factor | Health |
52-Week High | $34.57 | $185.50 |
52-Week Low | $26.71 | $123.10 |
Typical Hold Time | 45 Days | 23 Days |
Enterprise Value | — | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWS (iShares MSCI Singapore ETF) trades at $31.60, down 2.71% with bearish technical signals from moving averages and oscillators. The ETF recently hit 52-week highs amid Singapore's strong economic growth and AI momentum, attracting institutional interest including Amundi's 4.8% position increase. Key support sits at $31 with resistance at $32.
Outlook remains mixed with technical weakness offset by positive fundamental drivers. Investment opportunity lies in Singapore's economic resilience and AI-driven growth, though stretched valuations and bearish momentum present near-term risks. The ETF offers exposure to Asia's outperformance versus S&P 500 but faces volatility from regional economic sensitivity.
Neurocrine Biosciences (NBIX) trades at $142.44, down 0.72% with bearish technical signals but strong fundamentals including three consecutive quarterly EPS beats. The company shows robust profitability with 20.91% net margin and 22.09% ROE, supported by growing revenue from $2.9B to $3.4B projected. Recent news highlights pipeline development and conference participation.
Wall Street maintains strong bullish sentiment with 86% buy ratings and $204.18 consensus target, representing 43% upside. Key risks include INGREZZA pricing pressure in 2029 and execution challenges as the company diversifies beyond its main product. The stock offers growth potential but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Singapore ETF
EWS tracks the MSCI Singapore 25/50 Index, providing targeted exposure to large and mid-cap companies in Singapore. It is heavily weighted toward the financial, industrial, and real estate sectors, serving as a liquid tool for accessing Singapore's stable, dividend-oriented developed economy.
Read more on EWS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
